Medical technology firm Tempus is set to expand its comprehensive genomic profiling offering with the launch of xF+, it’s new non-invasive, liquid biopsy panel.

With 523 genes, the new liquid biopsy panel is claimed to be the largest available on the market. It focuses on pathogenic mutations in cell-free DNA (cfDNA).

The new xF+ panel covers more genes with single nucleotide variants and indels reported in all genes, as well as providing expanded coverage of translocations, or gene rearrangements, and copy number variants.

Furthermore, it has the capability to measure microsatellite instability (MSI), blood-based tumour mutational burden (bTMB) and predictive biomarkers for many cancer immunotherapies.

Tempus Translational Medicine vice-president Nike Beaubier said: “xF+ further strengthens Tempus’ range of genomic profiling capabilities, offering physicians a broad-panel liquid biopsy option for patients in which a comprehensive, non-invasive test is appropriate.

“We are excited to introduce what we believe is the largest clinically available liquid biopsy panel to provide even more insights on pathogenic mutations in cfDNA.”

The company stated that in parallel testing with tumour tissue, liquid biopsies help provide a comprehensive detection of actionable alterations compared to tissue or liquid biopsy testing alone.

A follow-up liquid biopsy test can also help to reveal new gene alterations and resistance mechanisms (clonal evolution), as well as sample tumour DNA shed from metastatic sites.

Lastly, it can be used for monitoring disease burden and response to treatment.

Tempus stated that xF+ will be available, along with its 105-gene liquid biopsy assay, xF, on a limited basis, with plans for a wider launch later in the year.

It noted that the xF+ panel is the newest addition to its library of assays, which includes xG, xG+, xF, xT and xE.